Coeptis Therapeutics (COEP) Competitors $13.97 +2.49 (+21.69%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$13.70 -0.27 (-1.93%) As of 08/15/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock COEP vs. BDTX, CTNM, ACTU, KRRO, MOLN, KYTX, NKTX, ACOG, THTX, and FTLFShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Black Diamond Therapeutics (BDTX), Contineum Therapeutics (CTNM), Actuate Therapeutics (ACTU), Korro Bio (KRRO), Molecular Partners (MOLN), Kyverna Therapeutics (KYTX), Nkarta (NKTX), Alpha Cognition (ACOG), Theratechnologies (THTX), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. Its Competitors Black Diamond Therapeutics Contineum Therapeutics Actuate Therapeutics Korro Bio Molecular Partners Kyverna Therapeutics Nkarta Alpha Cognition Theratechnologies FitLife Brands Black Diamond Therapeutics (NASDAQ:BDTX) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership. Is BDTX or COEP more profitable? Black Diamond Therapeutics' return on equity of 12.70% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A 12.70% 9.58% Coeptis Therapeutics N/A -216.96%-113.00% Which has more risk and volatility, BDTX or COEP? Black Diamond Therapeutics has a beta of 2.87, indicating that its share price is 187% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.59, indicating that its share price is 159% less volatile than the S&P 500. Does the media favor BDTX or COEP? In the previous week, Black Diamond Therapeutics had 18 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 21 mentions for Black Diamond Therapeutics and 3 mentions for Coeptis Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.95 beat Coeptis Therapeutics' score of 0.65 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Black Diamond Therapeutics Positive Coeptis Therapeutics Positive Do institutionals & insiders believe in BDTX or COEP? 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 6.0% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, BDTX or COEP? Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond TherapeuticsN/AN/A-$69.68M$0.2312.00Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.41 Do analysts rate BDTX or COEP? Black Diamond Therapeutics presently has a consensus price target of $12.40, indicating a potential upside of 349.28%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryBlack Diamond Therapeutics beats Coeptis Therapeutics on 12 of the 14 factors compared between the two stocks. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.34M$3.10B$5.68B$9.81BDividend YieldN/A2.23%3.79%4.12%P/E Ratio-2.4120.8931.0825.11Price / SalesN/A369.91468.25192.48Price / CashN/A42.3037.4059.05Price / Book8.688.659.096.18Net Income-$10.88M-$54.65M$3.26B$265.11M7 Day Performance25.18%6.56%7.36%4.22%1 Month Performance42.99%7.53%5.47%2.01%1 Year Performance245.96%13.69%30.61%23.75% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics0.5207 of 5 stars$13.97+21.7%N/A+236.5%$40.34MN/A-2.412Earnings ReportShort Interest ↑Gap UpHigh Trading VolumeBDTXBlack Diamond Therapeutics3.3233 of 5 stars$2.73-3.5%$12.80+368.9%-44.6%$155.23MN/A45.5090News CoverageAnalyst RevisionCTNMContineum Therapeutics3.497 of 5 stars$6.00+3.4%$22.50+275.0%-60.3%$155.22M$50M-3.0531Short Interest ↓ACTUActuate Therapeutics2.2681 of 5 stars$7.31+3.4%$20.50+180.4%-8.7%$149.64MN/A0.0010News CoverageEarnings ReportKRROKorro Bio1.452 of 5 stars$15.92+2.8%$102.43+543.4%-55.1%$149.49M$2.27M-1.6970Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionMOLNMolecular Partners2.5126 of 5 stars$3.67+0.4%$12.00+227.3%-44.1%$148.02M$2.23M-1.91180News CoveragePositive NewsKYTXKyverna Therapeutics2.5425 of 5 stars$3.41+1.2%$15.60+357.5%-49.6%$147.38M$7.03M-1.0196News CoverageEarnings ReportAnalyst RevisionNKTXNkarta2.0486 of 5 stars$2.07-2.4%$14.33+592.4%-53.5%$146.89MN/A-1.37140Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionACOGAlpha Cognition1.71 of 5 stars$9.09+4.0%$20.00+120.0%N/A$145.62MN/A-7.57N/ANews CoverageEarnings ReportAnalyst DowngradeTHTXTheratechnologiesN/A$3.16flatN/A+138.2%$145.30M$85.87M-16.63140Positive NewsShort Interest ↓FTLFFitLife Brands4.1367 of 5 stars$15.45+18.4%$20.50+32.7%+6.5%$145.08M$64.47M18.3920News CoverageEarnings ReportAnalyst ForecastGap UpHigh Trading Volume Related Companies and Tools Related Companies Black Diamond Therapeutics Alternatives Contineum Therapeutics Alternatives Actuate Therapeutics Alternatives Korro Bio Alternatives Molecular Partners Alternatives Kyverna Therapeutics Alternatives Nkarta Alternatives Alpha Cognition Alternatives Theratechnologies Alternatives FitLife Brands Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COEP) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access